Anti-TIGIT in PD-L1–High Advanced Non–Small Cell Lung Cancer: Insights From SKYSCRAPER-01 and the Path Forward
Mené sur 521 patients atteints d'un cancer du poumon non à petites cellules non résécable, de stade localement avancé ou métastatique et surexprimant fortement PD-L1, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité de l'ajout de tiragolumab à l'atézolizumab
Lung cancer remains the leading cause of cancer-related death worldwide, with non–small cell lung cancer (NSCLC) accounting for most cases.1 Over the past few decades, precision oncology has reshaped treatment landscape of advanced NSCLC. For patients harboring actionable oncogenic alterations, molecularly targeted therapies are now the standard. For patients without actionable drivers, immune checkpoint inhibitors targeting PD-1 or PD-L1 have transformed their first-line treatment. Importantly, for patients with high PD-L1 expression (defined as tumor proportion score ≥50%), PD-(L)1 inhibitor monotherapy has become an established chemotherapy-free standard.2 Nevertheless, primary and acquired resistance to PD-(L)1 blockade limits long-term benefit for many patients, underscoring an unmet clinical need.3
Journal of Clinical Oncology , éditorial, 2026